DOSSIER · 13F-HR · Q1 2026

SR ONE CAPITAL MANAGEMENT, LP

SR ONE's family office based in San Francisco, CA — $915M in tracked AUM across 14 positions as of Q1 2026.

SO

SR ONE·San Francisco, CA·Family Office

CIK 0001910264 · last filed Mar 31, 2026

Total AUM

$915M

▼ 18.8%

vs prior

Holdings

14

—

positions

Whale Score

75

75

strong

Activity

—

no data

changes this Q

Top sector

Tech

6% weight

concentration

AI Analysis · Q1 2026 · Q1 2026

Based on the SEC 13F filing for SR ONE CAPITAL MANAGEMENT, LP for the period ending September 30, 2025, here is a comprehensive analysis of the portfolio's structure, activity, and strategic orientation.

1. Portfolio Overview

SR ONE CAPITAL MANAGEMENT, LP manages a highly concentrated portfolio totaling approximately $595.16 million, distributed across just nine holdings. This represents a significant growth in portfolio value of 29.0% compared to the previous quarter ($461.38M). The firm e...

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight

01

Arcellx, Inc.

$269M2.3M29.4%

02

Veradermics, Inc.

$152M2.4M16.6%

03

Zenas BioPharma, Inc

$98M5.0M10.8%

04

CRISPR Therapeutics AG

$97M2.0M10.6%

05

Design Therapeutics, Inc.

$69M6.5M7.6%

06

ORIC Pharmaceuticals, Inc.

$58M4.5M6.4%

07

Alumis Inc.

$43M2.0M4.7%

08

Mineralys Therapeutics Inc.

$42M1.6M4.6%

09

ARS Pharmaceuticals, Inc.

$32M4.0M3.5%

10

Oruka Therapeutics, Inc

$21M430K2.3%

Filing history

Filing history loading…